Eczema and Psoriasis Treatments Are Working Better Than Ever—Here's What Changed in 2025

Revolutionary treatments for eczema and psoriasis are transforming patient outcomes in 2025, with new biologics achieving over 75% improvement rates and expanding treatment options for children as young as 2 years old. The shift away from traditional corticosteroids toward advanced targeted therapies is giving patients safer, more effective long-term solutions.

What Makes These New Eczema Treatments So Effective?

The biggest breakthrough for atopic dermatitis (eczema) comes from biologics that target specific inflammatory pathways. Dupilumab, which blocks IL-4 and IL-13 proteins, showed impressive results in a phase 4 trial including patients with skin of color. At 24 weeks, 76% of patients achieved at least 75% improvement in their Eczema Area and Severity Index (EASI 75), and 53% experienced significant itch relief within just 2 weeks.

Another game-changer is lebrikizumab, a selective IL-13 inhibitor that maintained effectiveness over 2 years. In patients with skin of color, 78.4% achieved EASI 75 improvement, and approximately 60% experienced meaningful itch reduction. Perhaps most exciting for patients, 79% of those taking lebrikizumab every 8 weeks maintained their improvement, offering hope for less frequent dosing.

How Are Children Benefiting From These Advances?

2025 marked a pivotal year for pediatric skin care with several new approvals specifically for young patients. These treatments address a long-standing gap in safe, effective options for children:

• Roflumilast cream: Approved for children aged 2 to 5 years with eczema, this PDE4 inhibitor achieved nearly 40% EASI 75 improvement after just 4 weeks, with itch relief starting within 24 hours of first application
• Ruxolitinib cream: Now approved for children aged 2 to 11 years, this JAK inhibitor showed 56.5% of patients achieved treatment success compared to only 10.8% with placebo
• Guselkumab: Became the first IL-23 inhibitor approved for pediatric plaque psoriasis, with 56% of patients achieving 90% improvement and 66% reaching clear or almost clear skin at 16 weeks

These approvals represent a major shift toward nonsteroidal options for younger patients, giving parents and doctors safer alternatives to traditional treatments.

What's New for Psoriasis Treatment?

Psoriasis treatments are achieving unprecedented long-term results. Bimekizumab, which targets both IL-17A and IL-17F proteins, demonstrated remarkable durability with approximately two-thirds of patients maintaining complete skin clearance for 4 years. Even more impressive, about 80% of patients achieved complete resolution of nail psoriasis over 3 years—a notoriously difficult-to-treat area.

The most promising development may be icotrokinra, an investigational oral IL-23 inhibitor. In phase 3 studies, 65% of patients achieved clear or almost clear skin, and 50% reached 90% improvement at 16 weeks, increasing to 65% at 24 weeks. This oral option showed high clearance rates for challenging areas like the scalp, genitals, and hands and feet.

For adults dealing with chronic hand eczema, delgocitinib became the first FDA-approved treatment specifically targeting this debilitating condition that affects 1 in 10 adults worldwide. This topical JAK inhibitor offers hope for patients who previously had limited options.

The trend is clear: 2025 has ushered in an era of pathogenesis-based, patient-centered approaches that are redefining standards of care. With over 7,000 patient-years of safety data supporting these new treatments, patients and doctors can feel confident about long-term use while achieving better outcomes than ever before.